{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:00:00Z","timestamp":1787317200001,"version":"build-2736575974"},"reference-count":70,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deanship of Research and Graduate Studies at King Khalid University","award":["RGP1\/59\/46"],"award-info":[{"award-number":["RGP1\/59\/46"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a global health challenge due to its complex pathophysiological processes. Systemic inflammation may profoundly affect disease progression, but the correlation between inflammatory markers and disease severity remains inadequately explored. This cross-sectional analysis within a prospective cohort evaluated associations of inflammatory markers (IL-6, TNF-\u03b1, hsCRP) with MASLD severity (five non-invasive scores) and metabolic indices, primarily with early-stage disease (66.7% mild fibrosis by TE). Methods: We recruited 120 patients diagnosed with MASLD. Assessment included anthropometric measurements, laboratory analyses, and non-invasive fibrosis evaluation using five validated scoring systems (APRI, FIB-4, NAFLD fibrosis score, FAST score, and transient elastography). Inflammatory markers were quantified using high-sensitivity ELISA techniques. Medication\/comorbidities were recorded (statins 23.3%, diabetes drugs 26.7%), and multivariate regressions and FDR correction were applied. Results: Patients showed remarkably elevated inflammatory markers compared to reference ranges: IL-6 (15.1 \u00b1 9.3 pg\/mL), TNF-\u03b1 (38.8 \u00b1 29.1 pg\/mL), and hsCRP (12.3 \u00b1 11.1 mg\/L). No correlations were found between inflammatory markers and disease severity across any non-invasive scoring system. However, TNF-\u03b1 correlated significantly with waist circumference (r = 0.28, p = 0.002) and ALT (r = 0.19, p = 0.03), while showing inverse correlations with total cholesterol (r = \u22120.27, p = 0.03) and LDL (r = \u22120.22, p = 0.02). In contrast, hsCRP correlated positively with LDL (r = 0.20, p = 0.02) and WBC count (r = 0.24, p = 0.008). Conclusion: This study reveals a dissociation between systemic inflammatory markers and hepatic fibrosis severity in MASLD. Inflammatory Markers showed stronger metabolic associations than fibrosis, limiting their utility as fibrosis surrogates in early MASLD. These findings support a dual-pathway approach to MASLD management, targeting metabolic and hepatic components independently. The divergent associations of TNF-\u03b1 and hsCRP with lipid profiles suggest distinct inflammatory mechanisms in MASLD.<\/jats:p>","DOI":"10.3390\/metabo16010025","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:50:21Z","timestamp":1766710221000},"page":"25","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Associations Between Systemic Inflammatory Markers, Metabolic Dysfunction, and Liver Fibrosis Scores in Patients with MASLD"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-8265","authenticated-orcid":false,"given":"Ragaey Ahmad","family":"Eid","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Infectious Diseases (Tropical Medicine Department), Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-1255","authenticated-orcid":false,"given":"Ahmed Moheyeldien","family":"Hamed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-5493","authenticated-orcid":false,"given":"Sara O.","family":"Elgendy","sequence":"additional","affiliation":[{"name":"Clinical and Chemical Pathology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-2306","authenticated-orcid":false,"given":"Khalid M.","family":"Orayj","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha 62521, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-0853","authenticated-orcid":false,"given":"Ahmed R. N.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha 62521, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M. Abdel","family":"Hamied","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Nahda University (NUB), Beni-Suef 19206, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-5011","authenticated-orcid":false,"given":"Engy A.","family":"Wahsh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, October 6 University, Giza 12585, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Youssif","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, October 6 University, Giza 12585, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Rabea","sequence":"additional","affiliation":[{"name":"Department of Clinical pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin M.","family":"Madney","sequence":"additional","affiliation":[{"name":"Department of Clinical pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Attia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Infectious Diseases (Tropical Medicine Department), Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaymaa","family":"Nafady","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Infectious Diseases (Tropical Medicine Department), Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Youssif, M., Eid, R.A., Rabea, H., Madney, Y.M., Khaled, A., Orayj, K., Attia, D., and Wahsh, E.A. (2025). Evaluation of the Potential Benefits of Trimetazidine in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial. Pharmaceuticals, 18.","DOI":"10.3390\/ph18091279"},{"key":"ref_3","first-page":"A264","article-title":"IDDF2024-ABS-0333 Prevalence of dysplasia in the liver tissues of non-cirrhotic patients with non-alcoholic fatty liver disease (NAFLD)","volume":"73","author":"Eid","year":"2024","journal-title":"Clin. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Eid, R.A., Attia, D., Soliman, A.S., Abd Elmaogod, E.A., AbdelSalam, E.M., Rashad, A.M., Sayed, A.S.A., and Nabil, T.M. (2025). Impact of sleeve gastrectomy on the course of metabolic associated fatty liver disease. Indian J. Gastroenterol., 1\u201311.","DOI":"10.1007\/s12664-025-01757-9"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/joim.13380","article-title":"Inflammatory and fibrotic mechanisms in NAFLD\u2014Implications for new treatment strategies","volume":"291","author":"Lee","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Duan, Y., Pan, X., Luo, J., Xiao, X., Li, J., Bestman, P.L., and Luo, M. (2022). Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880298"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tylutka, A., Walas, \u0141., and Zembron-Lacny, A. (2024). Level of IL-6, TNF, and IL-1\u03b2 and age-related diseases: A systematic review and meta-analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1330386"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhao, J., Zhou, Q., Wang, Y., Xie, F., and Fan, J. (2025). Associations between composite systemic inflammation indicators (CAR, CLR, SII, AISI, SIRI, and CALLY) and metabolic dysfunction-associated fatty liver disease (MAFLD): Evidence from a two-stage study in China. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1702567"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/MOG.0000000000000621","article-title":"The utility of liver biopsy in 2020","volume":"36","author":"Khalifa","year":"2020","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s43066-024-00388-7","article-title":"Percutaneous radiofrequency ablation for stage B1 of modified Bolondi\u2019s subclassification for intermediate-stage hepatocellular carcinoma","volume":"14","author":"Eid","year":"2024","journal-title":"Egypt. Liver J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sabry, R.M., Hamad, O., Khalil, H.E., Mohammed, S.I., Eid, R.A., and Hosny, H. (2025). The role of multifocal visual evoked potential in detection of minimal hepatic encephalopathy in patients with compensated liver cirrhosis. BMC Neurol., 25.","DOI":"10.1186\/s12883-025-04031-9"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.jhepr.2025.101351","article-title":"Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials","volume":"7","author":"Fichez","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Qiu, X., Shen, S., Jiang, N., Feng, Y., Yang, G., and Lu, D. (2025). Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: A cross-sectional study of NHANES 2017\u20132020. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03625-4"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): A comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr. Obes. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes. Facts, 17, 374\u2013444.","DOI":"10.1159\/000539371"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s43066-025-00470-8","article-title":"Prevalence of spontaneous fungal peritonitis in Egyptian cirrhotic patients with ascites","volume":"15","author":"Abdelkader","year":"2025","journal-title":"Egypt. Liver J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.dld.2025.01.082","article-title":"The use of Controlled Attenuation Parameter for the assessment of treatment response in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease undergoing a lifestyle intervention program","volume":"57","author":"Vaira","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s41983-021-00348-7","article-title":"Quantitative motor unit potential analysis and nerve conduction studies for detection of subclinical peripheral nerve dysfunction in patients with compensated liver cirrhosis","volume":"57","author":"Elkholy","year":"2021","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kim, J., Ito, T., Arai, T., Atsukawa, M., Kawanaka, M., Toyoda, H., Honda, T., Yu, M.L., Yoon, E.L., and Jun, D.W. (2024). Modified FIB-4 index in type 2 diabetes mellitus with steatosis: A non-linear predictive model for advanced hepatic fibrosis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14222500"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bo\u0142dys, A., Bor\u00f3wka, M., Bu\u0142dak, \u0141., and Okopie\u0144, B. (2025). Impact of Short-Term Liraglutide Therapy on Non-Invasive Markers of Liver Fibrosis in Patients with MASLD. Metabolites, 15.","DOI":"10.3390\/metabo15080510"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sato, S., Iino, C., Chinda, D., Sasada, T., Tateda, T., Kaizuka, M., Nomiya, H., Igarashi, G., Sawada, K., and Mikami, T. (2023). Effect of Liver Fibrosis on Oral and Gut Microbiota in the Japanese General Population Determined by Evaluating the FibroScan\u2013Aspartate Aminotransferase Score. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713470"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zisis, M., Chondrogianni, M.E., Androutsakos, T., Rantos, I., Oikonomou, E., Chatzigeorgiou, A., and Kassi, E. (2025). Linking cardiovascular disease and metabolic Dysfunction-Associated steatotic liver disease (MASLD): The role of cardiometabolic drugs in MASLD treatment. Biomolecules, 15.","DOI":"10.3390\/biom15030324"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101777","DOI":"10.1016\/j.aohep.2025.101777","article-title":"From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Zhou","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13679-025-00657-5","article-title":"The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review","volume":"14","author":"Vachliotis","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"ref_26","first-page":"229","article-title":"Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease","volume":"136","author":"Kumar","year":"2012","journal-title":"Indian J. Med. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13052-024-01639-4","article-title":"Prevalence of autoimmune thyroiditis among children with autoimmune hepatitis","volume":"50","author":"Mogahed","year":"2024","journal-title":"Ital. J. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Farag, M.H., Shaaban, M.H., Abdelkader, H., Al Fatease, A., Elgendy, S.O., and Okasha, H.H. (2025). Predictors of Complications in Radiofrequency Ablation for Hepatocellular Carcinoma: A Comprehensive Analysis of 1000 Cases. Medicina, 61.","DOI":"10.3390\/medicina61030458"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23362","DOI":"10.1038\/s41598-024-74098-w","article-title":"Identifying patient subgroups in MASLD and MASH-associated fibrosis: Molecular profiles and implications for drug development","volume":"14","author":"Verschuren","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/HEP.0000000000000842","article-title":"Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline","volume":"81","author":"Patel","year":"2025","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vilar-Gomez, E., Yates, K.P., Kleiner, D.E., Behling, C., Cummings, O.W., Wilson, L.A., Liang, T., Jarasvaraparn, C., Loomba, R., and Schwimmer, J.B. (J. Hepatol., 2025). Genetic and non-genetic drivers of histological progression and regression in MASLD, J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2025.09.013"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s40001-024-02065-2","article-title":"High levels of serum hypersensitive C-reactive protein are associated with non-alcoholic fatty liver disease in non-obese people: A cross-sectional study","volume":"29","author":"Xia","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4103\/jfmpc.jfmpc_887_19","article-title":"Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study","volume":"9","author":"Kumar","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1038\/s41467-024-48956-0","article-title":"Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD","volume":"15","author":"Verschuren","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10238-015-0347-4","article-title":"Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients","volume":"16","author":"Fragoso","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.20896","article-title":"Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease","volume":"42","author":"Musso","year":"2005","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1478-3231.2005.01191.x","article-title":"Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis","volume":"26","author":"Abiru","year":"2006","journal-title":"Liver Int."},{"key":"ref_39","first-page":"goae089","article-title":"Active role of the immune system in metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Mori","year":"2024","journal-title":"Gastroenterol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","article-title":"Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-\u03b1 and IL-6","volume":"69","author":"Park","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nutres.2011.02.004","article-title":"Waist circumference is positively correlated with markers of inflammation and negatively with adiponectin in women with metabolic syndrome","volume":"31","author":"Ackermann","year":"2011","journal-title":"Nutr. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1017\/S0007114522002148","article-title":"Association between cytokine levels and anthropometric measurements: A population-based study","volume":"129","author":"Valmorbida","year":"2023","journal-title":"Br. J. Nutr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"G387","DOI":"10.1152\/ajpgi.1998.275.3.G387","article-title":"TNF-induced liver injury","volume":"275","author":"Bradham","year":"1998","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13679-023-00519-y","article-title":"The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease","volume":"12","author":"Vachliotis","year":"2023","journal-title":"Curr. Obes. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.cmet.2023.10.009","article-title":"The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"Sawada","year":"2023","journal-title":"Cell Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e186420","DOI":"10.1172\/JCI186420","article-title":"MASH: The nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Okoro, E.U. (2021). TNF\u03b1-induced LDL cholesterol accumulation involve elevated LDLR cell surface levels and SR-B1 downregulation in human arterial endothelial cells. Int. J. Mol. Sci., 22.","DOI":"10.21203\/rs.3.rs-267515\/v2"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1194\/jlr.R600021-JLR200","article-title":"The role of TNF-\u03b1 in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk","volume":"48","author":"Popa","year":"2007","journal-title":"J. Lipid Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): From bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00109-023-02379-4","article-title":"Soluble LDL-receptor is induced by TNF-\u03b1 and inhibits hepatocytic clearance of LDL-cholesterol","volume":"101","author":"Zegeye","year":"2023","journal-title":"J. Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4078\/jrd.2023.0040","article-title":"Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis","volume":"31","author":"Kwon","year":"2024","journal-title":"J. Rheum. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Nafari, A., Mohammadifard, N., Haghighatdoost, F., Nasirian, S., Najafian, J., Sadeghi, M., Roohafza, H., and Sarrafzadegan, N. (2022). High-sensitivity C-reactive protein and low-density lipoprotein cholesterol association with incident of cardiovascular events: Isfahan cohort study. BMC Cardiovasc. Disord., 22.","DOI":"10.1186\/s12872-022-02663-0"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-023-01836-w","article-title":"Interactive effect of increased high sensitive C-reactive protein and dyslipidemia on cardiovascular diseases: A 12-year prospective cohort study","volume":"22","author":"Bafei","year":"2023","journal-title":"Lipids Health Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107238","DOI":"10.1016\/j.vph.2023.107238","article-title":"Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention","volume":"153","author":"Ridker","year":"2023","journal-title":"Vasc. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein (a) and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Popa-Fotea, N.M., Ferdoschi, C.E., and Micheu, M.M. (2023). Molecular and cellular mechanisms of inflammation in atherosclerosis. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1200341"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e06","DOI":"10.15420\/usc.2024.25","article-title":"High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?","volume":"19","author":"Mehta","year":"2025","journal-title":"US Cardiol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Yassin, A., Eid, R.A., Mohammad, M.F., Elgendy, M.O., Mohammed, Z., Abdelrahim, M.E., Abdel Hamied, A.M., Binsuwaidan, R., Saleh, A., and Hussein, M. (2025). Microbial Multidrug-Resistant Organism (MDRO) Mapping of Intensive Care Unit Infections. Medicina, 61.","DOI":"10.3390\/medicina61071220"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1186\/s40001-025-03151-9","article-title":"Stratified cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): Impact of varying metabolic risk factor burden","volume":"30","author":"Elsabaawy","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12944-024-02425-1","article-title":"Lipids dysregulation in diseases: Core concepts, targets and treatment strategies","volume":"24","author":"Dakal","year":"2025","journal-title":"Lipids Health Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wang, W., Gao, X., Niu, W., Yin, J., and He, K. (2025). Targeting Metabolism: Innovative Therapies for MASLD Unveiled. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094077"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: A systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","article-title":"\u039cetabolic dysfunction-associated steatotic liver disease: A condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment","volume":"22","author":"Byrne","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zibaeenejad, F., Mohammadi, S.S., Sayadi, M., Safari, F., and Zibaeenezhad, M.J. (2022). Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: A cohort-based cross-sectional study. BMC Cardiovasc. Disord., 22.","DOI":"10.1186\/s12872-022-02601-0"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1001281","DOI":"10.37349\/emed.2025.1001281","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): A systemic disease with a variable natural history and challenging management","volume":"6","author":"Adinolfi","year":"2025","journal-title":"Explor. Med."},{"key":"ref_68","first-page":"47","article-title":"Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective","volume":"13","author":"Wang","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","article-title":"Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study","volume":"82","author":"Xiang","year":"2025","journal-title":"J. Hepatol."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/1\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T01:15:49Z","timestamp":1766711749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/1\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["metabo16010025"],"URL":"https:\/\/doi.org\/10.3390\/metabo16010025","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]}}}